Pathological response rate in hormone-positive breast cancer patients treated with neoadjuvant FEC and triweekly docetaxel: a case series

Takayoshi Kiba,1 Nao Morii,2,3 Hirotoshi Takahashi,2 Shinji Ozaki,2 Misao Atsumi,4 Fumi Masumoto,4 Hiroyasu Yamashiro,2,31Division of Modern Medical Technology, Institute for Clinical Research, 2Department of Breast Surgery, National Hospital Organization Kure Medical Center and Chugoku Cancer Cente...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kiba T, Morii N, Takahashi H, Ozaki S, Atsumi M, Masumoto F, Yamashiro H
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2015
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/60b3f94bd12b4359b7e82fb7f3ad6e01
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:60b3f94bd12b4359b7e82fb7f3ad6e01
record_format	dspace
spelling	oai:doaj.org-article:60b3f94bd12b4359b7e82fb7f3ad6e012021-12-02T00:58:10ZPathological response rate in hormone-positive breast cancer patients treated with neoadjuvant FEC and triweekly docetaxel: a case series1179-1314https://doaj.org/article/60b3f94bd12b4359b7e82fb7f3ad6e012015-08-01T00:00:00Zhttp://www.dovepress.com/pathological-response-rate-in-hormone-positive-breast-cancer-patients--peer-reviewed-article-BCTThttps://doaj.org/toc/1179-1314Takayoshi Kiba,1 Nao Morii,2,3 Hirotoshi Takahashi,2 Shinji Ozaki,2 Misao Atsumi,4 Fumi Masumoto,4 Hiroyasu Yamashiro,2,31Division of Modern Medical Technology, Institute for Clinical Research, 2Department of Breast Surgery, National Hospital Organization Kure Medical Center and Chugoku Cancer Center, Kure, Japan; 3Department of Breast Surgery, Tenri Hospital, Tenri, Nara, Japan; 4Clinical Trial Management Office, National Hospital Organization Kure Medical Center and Chugoku Cancer Center, Kure, JapanAbstract: We recently reported that neoadjuvant 5-FU, epirubicin, and cyclophosphamide (FEC) followed by weekly paclitaxel and/or trastuzumab induced a high pathological complete response (pCR) rate in hormone-negative patients. The present study examined the therapeutic efficacy of neoadjuvant FEC followed by triweekly docetaxel and/or trastuzumab in the treatment of hormone-positive patients. Between February 2012 and December 2013, 16 hormone-positive patients with local breast cancer (luminal A type: six patients; luminal B type: two patients; luminal HER2 type: eight patients) were included in the study. The histological type of the primary cancer was invasive ductal carcinoma in all patients. The cancer stages in the 16 women who received this regimen were stage I in five (31.3%), IIA in four (25.0%), IIB in five (31.3%), IIIB in one (6.3%), and IIIC in one (6.3%). Regarding clinical TNM classification, five patients were T1N0M0, one was T1N1M0, three were T2N0M0, five were T2N1M0, one was T3N2M0, and one was T4N0M0. The pCR was evaluated using resected tissue after neoadjuvant chemotherapy according to the evaluation criteria of the Japanese Breast Cancer Society. Patients were classified into pathologic responders (grade 2: 50.0% of all patients: 2/6 of luminal A type; 6/8 of Luminal HER2 type) and nonresponders (grades 0 and 1: 50.0% of all patients: 4/6 of luminal A type; 2/2 of luminal B type; 2/8 of luminal HER2 type) according to the grade of the tumor. The pCR rate was 0%. Hematologic and nonhematologic toxicity was reversible and manageable. This study demonstrated that neoadjuvant FEC followed by triweekly docetaxel and/or trastuzumab did induce a high pathologic response in luminal HER2 type, but not in luminal A and B types, and did not induce a high pCR rate in the hormone-positive patients.Keywords: luminal type, surgery, therapeutic efficacyKiba TMorii NTakahashi HOzaki SAtsumi MMasumoto FYamashiro HDove Medical PressarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENBreast Cancer: Targets and Therapy, Vol 2015, Iss default, Pp 245-250 (2015)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Kiba T Morii N Takahashi H Ozaki S Atsumi M Masumoto F Yamashiro H Pathological response rate in hormone-positive breast cancer patients treated with neoadjuvant FEC and triweekly docetaxel: a case series
description	Takayoshi Kiba,1 Nao Morii,2,3 Hirotoshi Takahashi,2 Shinji Ozaki,2 Misao Atsumi,4 Fumi Masumoto,4 Hiroyasu Yamashiro,2,31Division of Modern Medical Technology, Institute for Clinical Research, 2Department of Breast Surgery, National Hospital Organization Kure Medical Center and Chugoku Cancer Center, Kure, Japan; 3Department of Breast Surgery, Tenri Hospital, Tenri, Nara, Japan; 4Clinical Trial Management Office, National Hospital Organization Kure Medical Center and Chugoku Cancer Center, Kure, JapanAbstract: We recently reported that neoadjuvant 5-FU, epirubicin, and cyclophosphamide (FEC) followed by weekly paclitaxel and/or trastuzumab induced a high pathological complete response (pCR) rate in hormone-negative patients. The present study examined the therapeutic efficacy of neoadjuvant FEC followed by triweekly docetaxel and/or trastuzumab in the treatment of hormone-positive patients. Between February 2012 and December 2013, 16 hormone-positive patients with local breast cancer (luminal A type: six patients; luminal B type: two patients; luminal HER2 type: eight patients) were included in the study. The histological type of the primary cancer was invasive ductal carcinoma in all patients. The cancer stages in the 16 women who received this regimen were stage I in five (31.3%), IIA in four (25.0%), IIB in five (31.3%), IIIB in one (6.3%), and IIIC in one (6.3%). Regarding clinical TNM classification, five patients were T1N0M0, one was T1N1M0, three were T2N0M0, five were T2N1M0, one was T3N2M0, and one was T4N0M0. The pCR was evaluated using resected tissue after neoadjuvant chemotherapy according to the evaluation criteria of the Japanese Breast Cancer Society. Patients were classified into pathologic responders (grade 2: 50.0% of all patients: 2/6 of luminal A type; 6/8 of Luminal HER2 type) and nonresponders (grades 0 and 1: 50.0% of all patients: 4/6 of luminal A type; 2/2 of luminal B type; 2/8 of luminal HER2 type) according to the grade of the tumor. The pCR rate was 0%. Hematologic and nonhematologic toxicity was reversible and manageable. This study demonstrated that neoadjuvant FEC followed by triweekly docetaxel and/or trastuzumab did induce a high pathologic response in luminal HER2 type, but not in luminal A and B types, and did not induce a high pCR rate in the hormone-positive patients.Keywords: luminal type, surgery, therapeutic efficacy
format	article
author	Kiba T Morii N Takahashi H Ozaki S Atsumi M Masumoto F Yamashiro H
author_facet	Kiba T Morii N Takahashi H Ozaki S Atsumi M Masumoto F Yamashiro H
author_sort	Kiba T
title	Pathological response rate in hormone-positive breast cancer patients treated with neoadjuvant FEC and triweekly docetaxel: a case series
title_short	Pathological response rate in hormone-positive breast cancer patients treated with neoadjuvant FEC and triweekly docetaxel: a case series
title_full	Pathological response rate in hormone-positive breast cancer patients treated with neoadjuvant FEC and triweekly docetaxel: a case series
title_fullStr	Pathological response rate in hormone-positive breast cancer patients treated with neoadjuvant FEC and triweekly docetaxel: a case series
title_full_unstemmed	Pathological response rate in hormone-positive breast cancer patients treated with neoadjuvant FEC and triweekly docetaxel: a case series
title_sort	pathological response rate in hormone-positive breast cancer patients treated with neoadjuvant fec and triweekly docetaxel: a case series
publisher	Dove Medical Press
publishDate	2015
url	https://doaj.org/article/60b3f94bd12b4359b7e82fb7f3ad6e01
work_keys_str_mv	AT kibat pathologicalresponserateinhormonepositivebreastcancerpatientstreatedwithneoadjuvantfecandtriweeklydocetaxelacaseseries AT moriin pathologicalresponserateinhormonepositivebreastcancerpatientstreatedwithneoadjuvantfecandtriweeklydocetaxelacaseseries AT takahashih pathologicalresponserateinhormonepositivebreastcancerpatientstreatedwithneoadjuvantfecandtriweeklydocetaxelacaseseries AT ozakis pathologicalresponserateinhormonepositivebreastcancerpatientstreatedwithneoadjuvantfecandtriweeklydocetaxelacaseseries AT atsumim pathologicalresponserateinhormonepositivebreastcancerpatientstreatedwithneoadjuvantfecandtriweeklydocetaxelacaseseries AT masumotof pathologicalresponserateinhormonepositivebreastcancerpatientstreatedwithneoadjuvantfecandtriweeklydocetaxelacaseseries AT yamashiroh pathologicalresponserateinhormonepositivebreastcancerpatientstreatedwithneoadjuvantfecandtriweeklydocetaxelacaseseries
_version_	1718403386141835264

Pathological response rate in hormone-positive breast cancer patients treated with neoadjuvant FEC and triweekly docetaxel: a case series

Ejemplares similares